Schering-Plough selects metabolic compound for development
Schering-Plough has selected a compound identified in its ongoing collaboration with Pharmacopeia for preclinical development. The compound will be examined as a potential treatment for metabolic diseases, the companies said this week.
According to the firms’ collaboration agreement, Schering-Plough is responsible for further development of the compounds. Pharmacopeia is eligible to receive milestone payments if the program advances into late-stage clinical trials and future royalties on sales of resulting products.
Pharmacopeia and Schering-Plough have been collaborating on the discovery of novel compounds, for further research and development by Schering-Plough, since 1994. This latest compound is the collaboration’s sixth drug candidate currently in development. Presently, Schering-Plough is investigating a CXCR- 2 antagonist from the collaboration as a potential treatment for chronic obstructive pulmonary disease (COPD) in Phase I clinical trials.
This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.